STOCK TITAN

Xebra's THC and CBN Cannabis Infused Lemonade Accepted for Summer Listing in the Province of Ontario Where More Than 1,000 Cannabis Stores Operate

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Xebra Brands Ltd. (CSE: XBRA) (OTCQB: XBRAF) announces that its Vicious Citrus cannabis-infused lemonade has been accepted by the Ontario Cannabis Store (OCS) for sale in Ontario, Canada. This beverage combines 10mg of THC with 2mg of CBN and is among the few Canadian products containing CBN. Marketing efforts will commence ahead of its commercial production scheduled for June 20, with availability expected in summer 2022. Xebra's lemonade is noted for its emulsion technology, which underwent Phase I clinical trials, highlighting its commitment to product safety and quality.

Positive
  • Acceptance of Vicious Citrus Lemonade by Ontario Cannabis Store for sale.
  • Utilization of unique CBN ingredient, attracting consumer interest.
  • Scheduled commercial production and distribution planned for summer 2022.
  • Engagement of a sales and marketing agency to promote the product.
Negative
  • None.

VANCOUVER, BC, April 12, 2022 /PRNewswire/ - Xebra Brands Ltd. ("Xebra") (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, is pleased to announce that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada.

Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol).  Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America. At the following link an article on CBN published by MJBizDaily:

https://mjbizdaily.com/cannabinoid-cbn-might-be-surprise-hit-in-cannabis-industry/

Marketing of Xebra's Vicious Citrous Lemonade can now begin in Ontario, where some 1,143 retail cannabis store licences have been issued, making it by far the most lucrative cannabis market in Canada. Commercial production is scheduled for June 20th, and product is expected to be available on store shelves in Ontario, and in other provinces this coming summer. Xebra has engaged a cannabis sales & marketing agency to introduce Vicious Citrus Lemonade to Canadian cannabis retailers.

In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone Phase I human clinical trials. The trial was carried-out with the approval of Health Canada. Xebra believes that as the cannabis industry develops, that consumers will demand better and safer products, and that claims about characteristics such as absorption, homogeneity, bioavailability, and shelf-life will be more closely scrutinized by regulators, such as the U.S. FDA, and Health Canada.

ON BEHALF OF THE BOARD:

Rodrigo Gallardo
President

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to provide economic, environmental, social, or any benefits of any type, in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Colombia, Canada, the Netherlands, or elsewhere; its ability to successfully apply for and obtain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to cultivate, grow, or process hemp or cannabis in Mexico, Colombia, Canada, the Netherlands, or elsewhere and related plans; financial, operational, or any other term or statement relating to the Company's participation in the Dutch medicinal cannabis cultivation pilot trial, including guaranteed revenue projections and any deliverable timelines; its ability to manufacture cannabis beverages, wellness products, or other products; its ability to commercialize or sell cannabis beverages, wellness products, or other products, in Mexico, Colombia, Canada, the Netherlands, or elsewhere; its ability to launch, commercialize or to sell Vicious Citrus Lemonade in 2022 or at any time, in any jurisdiction, and its related plans and claims, including market interest; its ability to commercialize or to sell Elements wellness products in any jurisdiction at any time; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs and production activity in Mexico or any jurisdiction; events or developments that XEBRA expects to take place in the future; general economic conditions; and other risk factors described in the prospectus of the Company dated September 30, 2021. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of XEBRA to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; and the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; the impact of DTC eligibility, or lack of, on the liquidity of the shares of XEBRA and the timely receipt of regulatory approval for license applications. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect XEBRA's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, XEBRA. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/xebras-thc-and-cbn-cannabis-infused-lemonade-accepted-for-summer-listing-in-the-province-of-ontario-where-more-than-1-000-cannabis-stores-operate-301523286.html

SOURCE Xebra Brands Ltd.

FAQ

What is Xebra Brands Ltd.'s latest product announcement?

Xebra Brands Ltd. announced the acceptance of its Vicious Citrus cannabis-infused lemonade for sale in Ontario.

When will Vicious Citrus Lemonade be available?

The commercial production of Vicious Citrus Lemonade is scheduled for June 20, with availability expected in summer 2022.

What are the key ingredients in Vicious Citrus Lemonade?

Vicious Citrus Lemonade contains 10mg of THC and 2mg of CBN.

What is unique about Xebra's Vicious Citrus Lemonade?

It is one of the few beverages in Canada containing CBN, which is gaining growing interest.

Who is responsible for marketing Xebra's new product?

Xebra has engaged a cannabis sales and marketing agency to introduce Vicious Citrus Lemonade to retailers.

XEBRA BRANDS LTD

OTC:XBRAF

XBRAF Rankings

XBRAF Latest News

XBRAF Stock Data

2.14M
54.35M
27.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver